Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

• Status: Withdrawn
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis is that GHRP-3 will exert beneficial effects on endothelial function and insulin resistance in older men and women via hormonal (GH, IGF-I, IGFBP-3,-1, insulin) and non-hormonal actions (anti-inflammatory).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tulane University Health Sciences Center
• Treatments: Hormones; Insulin; Mannitol; Secretagogues

Criteria

Inclusion Criteria:

1. Men and post-menopausal women 50-70 years.

2. Elevated fasting plasma glucose ranging <125 mg/dL

3. Waist circumference >35 inches in women and >40 inches in men

Exclusion Criteria:

1. Patients taking medications that may alter carbohydrate metabolism and/or insulin resistance.

2. Female patients with a positive pregnancy test.

3. Previous history of hypersensitivity to GHRP.

4. Patients with overt liver disease, renal disease and/or congestive heart failure.

5. Patients with anticipated change in medication regimen during the study period.

6. Current use or history of use of hormone replacement therapy in the last six months.

7. Current use or history of use of Ace Inhibitors or Angiotensin receptor blockers in the last six months.

8. Hemoglobin of < 11.6 g/dL for women and < 12.9 g/dL for men.